 |
What's it Worth? A Journal Club PodcastAuthor: Diana Langworthy
Get into the weeds with us as we take deep dives into clinical trials and build the essential skills of evidence critique! This podcast is a tool for healthcare professions students and practitioners to sharpen their science sleuth skills, learn key concepts about study design, biostatistics, and application of evidence to clinical practice. Language: en Genres: Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
S3E9 | Glucose-Lowering Drugs and COPD Exacerbations — Dual Benefits of SGLT2 and GLP-1 Therapy?
Episode 9
Tuesday, 4 November, 2025
New population-based study suggests SGLT2 inhibitors and GLP-1 receptor agonists may reduce COPD exacerbations in patients with type 2 diabetes. In this episode of What's It Worth?, we examine a large real-world study assessing whether glucose-lowering medications influence the risk of COPD exacerbations in patients with type 2 diabetes and chronic obstructive pulmonary disease. We focus on SGLT2 inhibitors and GLP-1 receptor agonists and discuss whether potential pulmonary benefits should influence drug selection in patients with both conditions. Guest: Ashley Wilke, PharmD — PGY2 Critical Care Pharmacy Resident at M Health Fairview East Bank Hospital. Study at a Glance Design: Retrospective cohort study using nationwide claims and registry data Population: Adults with type 2 diabetes and COPD initiating glucose-lowering therapy Exposures: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors Primary outcome: COPD exacerbations requiring hospitalization or systemic steroids Key Finding: SGLT2 inhibitors and GLP-1 receptor agonists were associated with a lower risk of COPD exacerbations compared with DPP-4's KEY Caveats: Results are observational and this study cannot prove causality - only association. Tune in for our conclusions when we ask, "What's it Worth?"! Key teaching points 1. SGLT2 inhibitors and GLP-1 RAs may reduce pulmonary inflammation and fluid overload, potentially contributing to fewer exacerbations. 2. In a patient with both COPD and type 2 diabetes, these agents may offer meaningful extra-glycemic benefits. 3. This evidence supports shared decision-making, not mandatory therapy selection 4. Pharmacists can identify dual-benefit opportunities and tailor therapy based on comorbidities, cardiovascular risk, and exacerbation history. Citation: Patorno E, Feldman HA, Bykov K, et al. Glucose-lowering medications and risk of chronic obstructive pulmonary disease exacerbations in type 2 diabetes. JAMA Intern Med. 2025;185(4):405-414. doi:10.1001/jamainternmed.2024.7811 🎧 If you find this episode helpful, follow and leave a quick rating—it helps other clinicians and learners find high-quality, evidence-based content. 🎧 Email me at whatsitworthpodcast@gmail.com if you have an article suggestion for me to decode!
